Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products
厌氧制造和分子分析过程优化支持活生物治疗产品的临床开发
基本信息
- 批准号:10482472
- 负责人:
- 金额:$ 97.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-04 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAllergensAllergicAllergic DiseaseAllergic inflammationAnaerobic BacteriaAnaphylaxisAntioxidantsAsthmaAtopic DermatitisBacteriaBiochemical PathwayBiological MarkersBiological Response Modifier TherapyBioreactorsCellsChildChildhoodChronicClinicalClinical ResearchClinical TrialsCyclic GMPData SetDesiccationDevelopmentDiseaseDisease modelEconomic BurdenEnvironmental Risk FactorEosinophiliaEvaluationExcipientsExtrinsic asthmaFecesFlow CytometryFood HypersensitivityFormulationFreeze DryingFreezingGoalsHealthcareHumanHypersensitivityIgEImmediate hypersensitivityImmuneImmune ToleranceImmunologicsImpairmentIndividualInfantInfiltrationInterleukin-4InterventionLactobacillusLicensingLifeLinkLungLymphMediatingMetagenomicsMethodsMicrobeMolecularMorbidity - disease rateOnset of illnessOralPharmaceutical PreparationsPharmacologic SubstancePhasePhase I Clinical TrialsPhase II Clinical TrialsPowder dose formPreventionPrimary PreventionProbioticsProcessProductionPublic HealthQuality of lifeReactionRecoveryRegulatory T-LymphocyteReportingRiskSecondary PreventionSupplementationSymptomsSystemTemperatureTestingTh2 CellsTherapeuticTrainingUnited States Food and Drug AdministrationUpdateValidationWorkallergic airway inflammationanalytical methodbasecapsuleclinical developmentclinical efficacyclinical materialcommensal bacteriacommercializationcostdesigndisorder preventiondisorder riskglobal healthgut microbiotaimmunoregulationimprovedin vivoinnovationliquid formulationmembermethod developmentmicrobialmouse modelnovelnovel strategiespotency testingpre-clinicalpreventprocess optimizationproduct developmentprogramsstandard of caresuccesstherapeutic candidate
项目摘要
ABSTRACT
Allergic diseases including atopic dermatitis, food allergy, and allergic asthma represent a global health problem
that disproportionately impacts children. Surprisingly, there are no approved approaches to prevent the
development of these diseases in at-risk individuals, resulting in chronic morbidity and economic burden. The
management of asthma, for example, carries a steep cost burden of billions of dollars per year in the US alone,
of which nearly 20 billion is spent on standard of care treatments with variable efficacy. Food allergy management
is generally limited to allergen avoidance and rescue from severe acute anaphylaxis. There is a crucial need to
develop innovative strategies to prevent the onset of these Type 1 allergic diseases rather than treating their
symptoms. A preventative approach targeting at-risk individuals could significantly reduce the morbidity and
healthcare burden associated with these increasingly common conditions.
Studies confirm the link between gut microbiota development, immunological training, and allergic disease onset
in childhood, and it is now clear that allergic disease risk is associated with aberrant microbial exposures over
the first year of life. Longitudinal gut microbiota profiling studies in infants and children show that a loss of specific
immunomodulatory commensal bacteria, and their metabolic networks, precedes allergic disease development.
Using infant gut microbiota data sets and in vivo allergic disease models, Siolta Therapeutics has designed a
live biotherapeutic product (LBP), STMC-103H, to stimulate tolerant immunological development and prevent
allergic disease onset in at-risk individuals. STMC-103H contains three distinct active ingredient bacteria isolated
from healthy human stool. Siolta has performed extensive cGMP manufacturing development, including
formulation, process, and analytical method development, to support Phase 1 and Phase 2 clinical trials of
STMC-103H under an IND with the FDA.
In this project, we will build on our previous STMC-103H drug product development to improve the stability,
potency, and characterization approaches for late-stage clinical trials and subsequent commercialization.
Success of this project will directly support the regulatory and commercial development of STMC-103H.
Indirectly, this work will improve the manufacturing and clinical development of diverse candidate LBPs
containing sensitive live bacteria with high therapeutic potential. Siolta will also seek to license novel
manufacturing approaches to other LBP developers.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ricardo Valladares其他文献
Ricardo Valladares的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ricardo Valladares', 18)}}的其他基金
A Synergistic Multistrain Live Biotherapeutic Product for the Prevention and Treatment of Necrotizing Enterocolitis
用于预防和治疗坏死性小肠结肠炎的协同多菌株活生物治疗产品
- 批准号:
10761298 - 财政年份:2023
- 资助金额:
$ 97.91万 - 项目类别:
Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products
厌氧制造和分子分析过程优化支持活生物治疗产品的临床开发
- 批准号:
10561682 - 财政年份:2022
- 资助金额:
$ 97.91万 - 项目类别:
相似海外基金
Measurement of serum IgE and identification of allergens in seafood allergic patients
海鲜过敏患者血清IgE测定及过敏原鉴定
- 批准号:
21K13490 - 财政年份:2021
- 资助金额:
$ 97.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of augmentation of contact allergic reactions by irritants and contact allergens
刺激物和接触性过敏原增强接触性过敏反应的机制
- 批准号:
335858052 - 财政年份:2017
- 资助金额:
$ 97.91万 - 项目类别:
Research Grants
Elucidation of conformational epitopes of peanut allergens essential for allergic reactions
阐明过敏反应所必需的花生过敏原的构象表位
- 批准号:
8970024 - 财政年份:2015
- 资助金额:
$ 97.91万 - 项目类别:
Environmental allergens affect the function of allergic inflammatory cells
环境过敏原影响过敏性炎症细胞的功能
- 批准号:
26860758 - 财政年份:2014
- 资助金额:
$ 97.91万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Effects of allergens on dendritic cell function in allergic asthma
过敏原对过敏性哮喘树突状细胞功能的影响
- 批准号:
nhmrc : 303161 - 财政年份:2004
- 资助金额:
$ 97.91万 - 项目类别:
NHMRC Project Grants
IImmune Tolerance Network: Airborne Allergens and Allergic Rhintitis
II免疫耐受网络:空气中的过敏原和过敏性鼻炎
- 批准号:
8348615 - 财政年份:2001
- 资助金额:
$ 97.91万 - 项目类别:
IImmune Tolerance Network: Airborne Allergens and Allergic Rhintitis
II免疫耐受网络:空气中的过敏原和过敏性鼻炎
- 批准号:
8522031 - 财政年份:2001
- 资助金额:
$ 97.91万 - 项目类别:
IImmune Tolerance Network: Airborne Allergens and Allergic Rhintitis
II免疫耐受网络:空气中的过敏原和过敏性鼻炎
- 批准号:
8730013 - 财政年份:2001
- 资助金额:
$ 97.91万 - 项目类别:
ASPERGILLUS ALLERGENS AND ALLERGIC ASPERGILLOSIS
曲霉过敏原和过敏性曲霉病
- 批准号:
6137243 - 财政年份:1998
- 资助金额:
$ 97.91万 - 项目类别:
ASPERGILLUS ALLERGENS AND ALLERGIC ASPERGILLOSIS
曲霉过敏原和过敏性曲霉病
- 批准号:
2462172 - 财政年份:1998
- 资助金额:
$ 97.91万 - 项目类别: